Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

TxCell Raises EUR 12.4 Million (USD 16 million) in a Third Financing Round

Published: Tuesday, November 27, 2012
Last Updated: Tuesday, November 27, 2012
Bookmark and Share
InnoBio fund supports TxCell development.

TxCell SA has announced that it raised EUR 12.4 million in a third financing round. This additional capital was provided by the InnoBio fund, managed by CDC Entreprises, for EUR six million and by TxCell’s existing shareholders Auriga Partners and Seventure Partners.

These additional financial resources will enable TxCell to pursue the development of its lead product candidate, Ovasave®.

Ovasave is an antigen-specific Treg cell-based immunotherapy for the treatment of Crohn’s disease in patients who are refractory to current treatments.

“The technology platform developed by TxCell offers a promising new therapeutic alternative for the many patients with severe chronic inflammatory diseases and who are refractory to current treatments,” said Laurent Arthaud, deputy CEO at CDC Entreprises.

Arthaud continued, “We are impressed by the innovative therapeutic approach and the encouraging positive clinical data obtained so far by TxCell. The company has a strong and experienced management team in place and capital injection will provide the necessary resources to confirm the clinical findings obtained so far and reach the next important development milestone.”

To date, TxCell has completed a first in man PhI/II clinical study carried out in France to evaluate the tolerability and efficacy of Ovasave.

The results showed good tolerance and a positive efficacy signal. This was particularly impressive in the best dose group with 75 per cent of patients treated responding.

The study results have just been published in Gastroenterology, the most prominent journal in the field of gastrointestinal diseases and featured in Nature Reviews Gastroenterology and Hepatology.

These promising results meant that TxCell decided to pursue the clinical development of Ovasave in the same patient population by performing a larger international blinded and placebo controlled phase IIb study.

“TxCell is now armed to move forward and to execute its business plan,” said Francois Meyer, chairman and chief executive officer at TxCell. “We value highly the support of InnoBio, as it acknowledges and validates our pioneering cell-based therapeutic approach for treating diseases with high unmet medical need. We also highly appreciate the continued support from our existing investors. This further investment gives us the necessary financial flexibility to progress as a leader in the emerging field of cell-based immunotherapies.”

TxCell has been funded by venture capital since 2004. A total of EUR 23.9 million has been invested in A/B rounds by five major investors, Auriga Partners, AXA Private Equity, CDC Entreprises via BioAm Fund, Innovation Capital and Seventure.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

TxCell Appoints Global Scientific Advisory Board
SAB contains world-leading experts in immunology, T-cell biology and chimeric antigen receptors.
Friday, April 01, 2016
TxCell Appoints PCT as its US Manufacturing Partner
TxCell personalized cellular immunotherapies using regulatory T-cells to treat severe chronic inflammatory and autoimmune diseases, announces the appointment of PCT, a Caladrius Company, as its contract manufacturing organization (CMO) in the US.
Wednesday, March 16, 2016
TxCell Reaches Key Milestone
Successful manufacturing validation runs of Ovasave paving the way for a resumption of the CATS29 phase IIb trial in Crohn’s disease in Q2 2016 as planned.
Friday, February 26, 2016
TxCell Signs Strategic Agreement with MaSTherCell
Agreement for European manufacturing of its cell therapy products.
Saturday, December 05, 2015
TxCell Re-acquires Full Rights to its Lead Product Ovasave®
Agreement between TxCell and Trizell to terminate the exclusive option.
Thursday, December 03, 2015
TxCell to Present its Cellular Immunotherapy Developments
Dr. Miguel Forte and Dr. Arnaud Foussat will present at three forthcoming leading cell and gene therapy and ophthalmology conferences.
Friday, September 18, 2015
TxCell Granted US Orphan Drug Designation for Col-Treg
A first-in-man clinical study is planned to start in 2016, with top line results expected end 2017.
Tuesday, September 15, 2015
TxCell Announces Publication of Preclinical Efficacy Results for Col-Treg
Results published in Investigative Ophthalmology and Visual Science (IOVS) provide details on the demonstration of Col-Treg’s therapeutic potential in autoimmune uveitis and will support its ongoing clinical development.
Thursday, September 10, 2015
TxCell Receives Fast Track Designation from FDA for Ovasave®
TxCell’s lead product designated for the treatment of moderate to severe Crohn’s disease.
Wednesday, August 05, 2015
TxCell Appoints MaSTherCell for the Manufacturing of Ovasave®
First clinical batches could be manufactured as soon as Q2 2016.
Saturday, August 01, 2015
TxCell Announces FDA Acceptance of IND for Ovasave
IND grants TxCell option of extending current phase 2b study from EU to US.
Tuesday, June 30, 2015
TxCell Announces a Temporary Partial Hold of Activities at its Pilot Manufacturing Unit
Company expects only potential limited impact on clinical product timeline.
Wednesday, June 24, 2015
TxCell: Financial Information for the First Quarter of 2015
Company reports its revenues for 1Q 2015.
Thursday, May 14, 2015
TxCell Appoints Stéphane Boissel as Chief Executive Officer
Company promotes Miguel Forte to Chief Operating Officer.
Saturday, May 02, 2015
TxCell and Trizell Amend Collaboration Agreement
Company appoints the Cell Therapy Catapult to perform process and manufacturing development.
Friday, May 01, 2015
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
One Step Closer to Precision Medicine for Chronic Lung Disease Sufferers
A study led by University of North Carolina at Chapel Hill, and National Jewish Health, has provided evidence of links between SNPs and known COPD blood protein biomarkers.
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
C Dots Show Powerful Tumor Killing Effect
Nanoparticles known as Cornell dots, or C dots, have shown great promise as a therapeutic tool in the detection and treatment of cancer.
Charles River Acquires Agilux
Enhances Charles River’s early-stage capabilities in bioanalytical services.
Faecal Bacteria Linked to Body Fat
Researchers at King’s College London have found a new link between the diversity of bacteria in human poo – known as the human faecal microbiome - and levels of abdominal body fat.
How Baby’s Genes Influence Birth Weight And Later Life Disease
The large-scale study could help to target new ways of preventing and treating these diseases.
Genes Underlying Dogs’ Social Ability Revealed
The social ability of dogs is affected by genes that also seem to influence human behaviour, according to a new study from Linköping University in Sweden.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!